- Home
- CLPT vs CAPR Comparison
CLPT vs CAPR Comparison
Compare CLPT & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLPT
- CAPR
- Stock Information
- Founded
- CLPT 1998
- CAPR 2005
- Country
- CLPT United States
- CAPR United States
- Employees
- CLPT N/A
- CAPR N/A
- Industry
- CLPT Medical/Dental Instruments
- CAPR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CLPT Health Care
- CAPR Health Care
- Exchange
- CLPT Nasdaq
- CAPR Nasdaq
- Market Cap
- CLPT 317.4M
- CAPR 324.6M
- IPO Year
- CLPT N/A
- CAPR N/A
- Fundamental
- Price
- CLPT $10.49
- CAPR $6.28
- Analyst Decision
- CLPT Strong Buy
- CAPR Strong Buy
- Analyst Count
- CLPT 3
- CAPR 8
- Target Price
- CLPT $27.67
- CAPR $24.75
- AVG Volume (30 Days)
- CLPT 375.5K
- CAPR 1.4M
- Earning Date
- CLPT 08-12-2025
- CAPR 08-11-2025
- Dividend Yield
- CLPT N/A
- CAPR N/A
- EPS Growth
- CLPT N/A
- CAPR N/A
- EPS
- CLPT N/A
- CAPR N/A
- Revenue
- CLPT $33,593,000.00
- CAPR $13,392,150.00
- Revenue This Year
- CLPT $22.34
- CAPR N/A
- Revenue Next Year
- CLPT $25.50
- CAPR $6,061.53
- P/E Ratio
- CLPT N/A
- CAPR N/A
- Revenue Growth
- CLPT 19.68
- CAPR N/A
- 52 Week Low
- CLPT $9.76
- CAPR $3.98
- 52 Week High
- CLPT $19.22
- CAPR $23.40
- Technical
- Relative Strength Index (RSI)
- CLPT 44.46
- CAPR 36.33
- Support Level
- CLPT $10.42
- CAPR $6.17
- Resistance Level
- CLPT $10.88
- CAPR $7.30
- Average True Range (ATR)
- CLPT 0.52
- CAPR 0.43
- MACD
- CLPT -0.01
- CAPR -0.11
- Stochastic Oscillator
- CLPT 22.75
- CAPR 4.53
About CLPT ClearPoint Neuro Inc.
ClearPoint Neuro Inc is a medical device company based in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance. The company's ClearPoint system, which is in commercial use, is used to perform minimally invasive surgical procedures in the brain. The company's products include the ClearPoint system, ClearPoint Services, ClearPoint Disposables, ClearPoint Software, and ClearPoint Therapeutic Solutions.
About CAPR Capricor Therapeutics Inc.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.